Cargando…

Targeting PD-L1 in non-small cell lung cancer using CAR T cells

Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) develops in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ming, Wang, Xu, Li, Wei, Yu, Xinfang, Flores-Villanueva, Pedro, Xu-Monette, Zijun Y., Li, Ling, Zhang, Mingzhi, Young, Ken H., Ma, Xiaodong, Li, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426958/ https://www.ncbi.nlm.nih.gov/pubmed/32792499 http://dx.doi.org/10.1038/s41389-020-00257-z

Ejemplares similares

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Severe delayed pulmonary toxicity following PD‐L1–specific CAR‐T cell therapy for non‐small cell lung cancer
por: Liu, Heping, et al.
Publicado: (2020)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
por: Yu, Xinfang, et al.
Publicado: (2021)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
por: Huang, Qian, et al.
Publicado: (2018)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
por: Huang, Qian, et al.
Publicado: (2018)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
por: Li, Xiangmin, et al.
Publicado: (2020)

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
por: Miao, Yi, et al.
Publicado: (2019)

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
por: Xie, Mingying, et al.
Publicado: (2022)

IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells
por: Dong, E, et al.
Publicado: (2021)

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
por: Liao, Qibin, et al.
Publicado: (2020)

Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin
por: Qiu, Yajuan, et al.
Publicado: (2019)

Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
por: Liu, Wei, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

PD-L1 expression is associated with advanced non-small cell lung cancer
por: Chen, Zhiquan, et al.
Publicado: (2016)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
por: Shi, Xiaojuan, et al.
Publicado: (2019)

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
por: Li, Yue, et al.
Publicado: (2022)

PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
por: Wu, Xiaodong, et al.
Publicado: (2020)

PD-L1 and c-MET expression and survival in patients with small cell lung cancer
por: Miao, Lulu, et al.
Publicado: (2017)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
por: Liu, Li, et al.
Publicado: (2023)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
por: Lu, Tingxun, et al.
Publicado: (2023)

Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant
por: Deng, Qipan, et al.
Publicado: (2019)

PD‐1/PD‐L1 co‐location: A novel biomarker for immunotherapy response in non‐small cell lung cancer
por: Diao, Xiayao, et al.
Publicado: (2022)

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
por: Ma, Hong Yun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ks5shvikr24ujj1qeg9i72m8hs